ABOUT US

We develop microfluidic based technologies for  high throughput drug screening in conjunction with 3-D cell culture. This technology is adaptable to a multitude of applications such as: disease modelling, drug discovery, drug re-purposing, toxicity testing of chemicals, microbial screening and personalized drug optimization. . .

Prof Mark Davies

Executive Chair & Founder

Executive Team

Dr Mark Lyons

Chief Executive Officer

Dr Finola Cliffe

Chief Operations Offier

Awards

Supported by